Valganciclovir for the prevention and treatment of cytomegalovirus disease in immunocompromised hosts

Raymund R Razonable, Carlos V. Paya

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Valganciclovir (Valcyte®, Roche), a prodrug of the deoxyguanosine analog ganciclovir (Cytovene®, Roche), is indicated for induction and maintenance treatment of cytomegalovirus retinitis in patients with AIDS and for prevention of cytomegalovirus disease in selected high-risk solid organ transplant recipients. After oral administration, valganciclovir is rapidly absorbed and converted to ganciclovir by intestinal and hepatic esterases. Valganciclovir is a highly recognized substrate of the intestinal peptide transporter PEPT1, which underlies the tenfold higher bioavailability of ganciclovir after valganciclovir compared to oral ganciclovir administration. At oral dose of 900 mg, valganciclovir provides a systemic ganciclovir exposure that is comparable to intravenous ganciclovir, at the standard dose of 5 mg/kg of body weight. Subsequent phosphorylation of ganciclovir, which occurs preferentially within cytomegalovirus-infected cells, results in the active metabolite, ganciclovir triphosphate, which is responsible for suppressing viral DNA synthesis by competitively inhibiting the incorporation of the natural substrate deoxyguanosine into viral DNA and thereby, terminating cytomegalovirus replication.

Original languageEnglish (US)
Pages (from-to)27-42
Number of pages16
JournalExpert Review of Anti-Infective Therapy
Volume2
Issue number1
StatePublished - Feb 2004

Fingerprint

Ganciclovir
Immunocompromised Host
Cytomegalovirus
Deoxyguanosine
Viral DNA
Therapeutics
Oral Administration
Cytomegalovirus Retinitis
valganciclovir
Prodrugs
Esterases
Biological Availability
Acquired Immunodeficiency Syndrome
Body Weight
Phosphorylation
Transplants
Liver

Keywords

  • AIDS
  • Congenital CMV infection
  • Cytomegalovirus
  • Ganciclovir
  • Hematopoietic stem cell transplantation
  • HIV prevention
  • Solid organ transplantation
  • Therapy
  • Valganciclovir

ASJC Scopus subject areas

  • Infectious Diseases
  • Parasitology

Cite this

Valganciclovir for the prevention and treatment of cytomegalovirus disease in immunocompromised hosts. / Razonable, Raymund R; Paya, Carlos V.

In: Expert Review of Anti-Infective Therapy, Vol. 2, No. 1, 02.2004, p. 27-42.

Research output: Contribution to journalArticle

@article{2835efa14ce54cdab31742e7c85ad5a7,
title = "Valganciclovir for the prevention and treatment of cytomegalovirus disease in immunocompromised hosts",
abstract = "Valganciclovir (Valcyte{\circledR}, Roche), a prodrug of the deoxyguanosine analog ganciclovir (Cytovene{\circledR}, Roche), is indicated for induction and maintenance treatment of cytomegalovirus retinitis in patients with AIDS and for prevention of cytomegalovirus disease in selected high-risk solid organ transplant recipients. After oral administration, valganciclovir is rapidly absorbed and converted to ganciclovir by intestinal and hepatic esterases. Valganciclovir is a highly recognized substrate of the intestinal peptide transporter PEPT1, which underlies the tenfold higher bioavailability of ganciclovir after valganciclovir compared to oral ganciclovir administration. At oral dose of 900 mg, valganciclovir provides a systemic ganciclovir exposure that is comparable to intravenous ganciclovir, at the standard dose of 5 mg/kg of body weight. Subsequent phosphorylation of ganciclovir, which occurs preferentially within cytomegalovirus-infected cells, results in the active metabolite, ganciclovir triphosphate, which is responsible for suppressing viral DNA synthesis by competitively inhibiting the incorporation of the natural substrate deoxyguanosine into viral DNA and thereby, terminating cytomegalovirus replication.",
keywords = "AIDS, Congenital CMV infection, Cytomegalovirus, Ganciclovir, Hematopoietic stem cell transplantation, HIV prevention, Solid organ transplantation, Therapy, Valganciclovir",
author = "Razonable, {Raymund R} and Paya, {Carlos V.}",
year = "2004",
month = "2",
language = "English (US)",
volume = "2",
pages = "27--42",
journal = "Expert Review of Anti-Infective Therapy",
issn = "1478-7210",
publisher = "Expert Reviews Ltd.",
number = "1",

}

TY - JOUR

T1 - Valganciclovir for the prevention and treatment of cytomegalovirus disease in immunocompromised hosts

AU - Razonable, Raymund R

AU - Paya, Carlos V.

PY - 2004/2

Y1 - 2004/2

N2 - Valganciclovir (Valcyte®, Roche), a prodrug of the deoxyguanosine analog ganciclovir (Cytovene®, Roche), is indicated for induction and maintenance treatment of cytomegalovirus retinitis in patients with AIDS and for prevention of cytomegalovirus disease in selected high-risk solid organ transplant recipients. After oral administration, valganciclovir is rapidly absorbed and converted to ganciclovir by intestinal and hepatic esterases. Valganciclovir is a highly recognized substrate of the intestinal peptide transporter PEPT1, which underlies the tenfold higher bioavailability of ganciclovir after valganciclovir compared to oral ganciclovir administration. At oral dose of 900 mg, valganciclovir provides a systemic ganciclovir exposure that is comparable to intravenous ganciclovir, at the standard dose of 5 mg/kg of body weight. Subsequent phosphorylation of ganciclovir, which occurs preferentially within cytomegalovirus-infected cells, results in the active metabolite, ganciclovir triphosphate, which is responsible for suppressing viral DNA synthesis by competitively inhibiting the incorporation of the natural substrate deoxyguanosine into viral DNA and thereby, terminating cytomegalovirus replication.

AB - Valganciclovir (Valcyte®, Roche), a prodrug of the deoxyguanosine analog ganciclovir (Cytovene®, Roche), is indicated for induction and maintenance treatment of cytomegalovirus retinitis in patients with AIDS and for prevention of cytomegalovirus disease in selected high-risk solid organ transplant recipients. After oral administration, valganciclovir is rapidly absorbed and converted to ganciclovir by intestinal and hepatic esterases. Valganciclovir is a highly recognized substrate of the intestinal peptide transporter PEPT1, which underlies the tenfold higher bioavailability of ganciclovir after valganciclovir compared to oral ganciclovir administration. At oral dose of 900 mg, valganciclovir provides a systemic ganciclovir exposure that is comparable to intravenous ganciclovir, at the standard dose of 5 mg/kg of body weight. Subsequent phosphorylation of ganciclovir, which occurs preferentially within cytomegalovirus-infected cells, results in the active metabolite, ganciclovir triphosphate, which is responsible for suppressing viral DNA synthesis by competitively inhibiting the incorporation of the natural substrate deoxyguanosine into viral DNA and thereby, terminating cytomegalovirus replication.

KW - AIDS

KW - Congenital CMV infection

KW - Cytomegalovirus

KW - Ganciclovir

KW - Hematopoietic stem cell transplantation

KW - HIV prevention

KW - Solid organ transplantation

KW - Therapy

KW - Valganciclovir

UR - http://www.scopus.com/inward/record.url?scp=2942589046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942589046&partnerID=8YFLogxK

M3 - Article

C2 - 15482169

AN - SCOPUS:2942589046

VL - 2

SP - 27

EP - 42

JO - Expert Review of Anti-Infective Therapy

JF - Expert Review of Anti-Infective Therapy

SN - 1478-7210

IS - 1

ER -